How has been the historical performance of Alembic Pharma?

Answer:The historical performance of Alembic Pharma shows a steady growth in net sales and operating income over the years, with net sales increasing from 3,934.68 Cr in Mar'19 to 6,672.08 Cr in Mar'25. The total operating income followed a similar trend, rising from 4,605.75 Cr in Mar'20 to 6,672.08 Cr in Mar'25. However, the total expenditure also increased significantly, from 3,061.10 Cr in Mar'19 to 5,663.84 Cr in Mar'25, impacting the operating profit, which peaked at 1,567.57 Cr in Mar'21 but has since declined to 1,050.79 Cr in Mar'25. The profit before tax saw fluctuations, reaching a high of 1,368.08 Cr in Mar'21 and settling at 706.31 Cr in Mar'25. Profit after tax showed a similar pattern, peaking at 1,114.76 Cr in Mar'21 and decreasing to 581.14 Cr in Mar'25. The earnings per share (EPS) also reflected this decline, dropping from 59.94 in Mar'21 to 29.68 in Mar'25. On the balance sheet, total assets increased from 5,989.05 Cr in Mar'20 to 7,606.90 Cr in Mar'25, while total liabilities rose from 5,989.05 Cr to 7,606.90 Cr in the same period. Cash flow from operating activities decreased significantly from 1,463.00 Cr in Mar'21 to 87.00 Cr in Mar'25, indicating challenges in generating cash from core operations.

Breakdown:
Alembic Pharma's financial performance has demonstrated a consistent upward trajectory in net sales, which rose from 3,934.68 Cr in Mar'19 to 6,672.08 Cr in Mar'25, alongside total operating income that mirrored this growth. Despite this increase, total expenditure surged from 3,061.10 Cr in Mar'19 to 5,663.84 Cr in Mar'25, leading to a decline in operating profit from its peak of 1,567.57 Cr in Mar'21 to 1,050.79 Cr in Mar'25. Profit before tax and profit after tax also experienced fluctuations, with profit before tax reaching a high of 1,368.08 Cr in Mar'21 and dropping to 706.31 Cr in Mar'25, while profit after tax decreased from 1,114.76 Cr in Mar'21 to 581.14 Cr in Mar'25. The earnings per share reflected this downward trend, falling from 59.94 in Mar'21 to 29.68 in Mar'25. On the balance sheet, total assets increased significantly, indicating growth, but total liabilities also rose correspondingly, suggesting a need for careful management of financial obligations. The cash flow from operating activities saw a notable decline, emphasizing challenges in maintaining cash generation from core business operations.